低分子肝素雾化吸入治疗肺心脏病的疗效观察

目的探讨低分子肝素钙雾化吸入对慢性肺源性心脏病中的治疗价值。方法89例患者随机分为治疗组与对照组,对照组给予常规治疗,治疗组在常规治疗的基础上应用低分子肝素钙雾化吸入,100IU/kg,q12h,疗程10d,治疗前后监测肺平均动脉压、动脉血气分析、血凝及纤溶指标,治疗后评估疗效。结果临床疗效治疗组优于对照组(P<0.05),治疗组肺平均动脉压下降优于对照组(P<0.05),动脉血氧分压升高治疗组优于对照组(P<0.05),血凝及纤溶指标有变化但未引起出血现象,治疗组血浆凝血酶原时间、凝血酶时间在治疗前后比较有显著差异(P<0.05),治疗后治疗组与对照组比较血浆凝血酶原时间、凝血酶时间变化有显著差异(P<0.05)。结论低分子肝素钙雾化吸入可改善慢性肺源性心脏病的肺动脉压,改善肺通气功能。

The Effects of Low Molecular Weight Heparin Calcium Aerosol Iinhalation in Chronic Pulmonary Heart Patients

Objective To investigate the effects of LMWCa aerosol inhalation in chronic pulmonary heart patients. Methods 89 patients were randomly divided into two groups: the therapy group and the control group. The control group was routine treated. The therapy group was treated by LMWHCCa aerosol inhalation 100IU/kg q.12h than the control group. One course of treatment was 10 days. The other treatment of the therapy group was similar to the control group. The pulmonary average arte-rial pressure. the arterial blood-gas analysis, the blood coagulated and the fi brinolysis daras were determined. Results The therapy group was better than the control group in the clinical effi ciency (P<0.05), in declining pulmonary average arterial pressure (P<0.05) and improving the oxygen pressure of blood (P<0.05). The blood coagulated and the fi brinolysis datas had changed, but had no hemorrhage phenmenon; the datas of the plasma prothrombin time and the thrombin time had changed after treatment in the therapy group (P<0.05), after treatment, there was difference between the therapy group and the control group in the datas of the plasma prothrombin time and the thrombin time (P<0.05), Conclusion LMWHCa aerosol inhalation could improve clinical effi ciency, decline pulmonary arterial perssure and improve ventilate function.